Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Payables (2022 - 2025)

Historic Payables for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $318000.0.

  • Atara Biotherapeutics' Payables fell 8518.17% to $318000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $318000.0, marking a year-over-year decrease of 8518.17%. This contributed to the annual value of $4.4 million for FY2024, which is 1853.96% up from last year.
  • Latest data reveals that Atara Biotherapeutics reported Payables of $318000.0 as of Q3 2025, which was down 8518.17% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Atara Biotherapeutics' Payables ranged from a high of $12.8 million in Q2 2022 and a low of $318000.0 during Q3 2025
  • Moreover, its 4-year median value for Payables was $4.4 million (2024), whereas its average is $5.4 million.
  • In the last 5 years, Atara Biotherapeutics' Payables surged by 2694.54% in 2024 and then tumbled by 8518.17% in 2025.
  • Over the past 4 years, Atara Biotherapeutics' Payables (Quarter) stood at $6.9 million in 2022, then plummeted by 46.38% to $3.7 million in 2023, then rose by 18.54% to $4.4 million in 2024, then plummeted by 92.72% to $318000.0 in 2025.
  • Its Payables was $318000.0 in Q3 2025, compared to $1.8 million in Q2 2025 and $1.4 million in Q1 2025.